• Explore /
  • Poster
  • / Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.

Abstract Poster

Authors

Karen Kelly

Karen Kelly

UC Davis Comprehensive Cancer Center, Sacramento, CA

Karen Kelly , Manish R. Patel , Jeffrey R. Infante , Nicholas Iannotti , Petros Nikolinakos , Joseph Leach , Ding Wang , Jason Claud Chandler , Guy Heinrich Maria Jerusalem , Jayne S. Gurtler , Hendrik-Tobias Arkenau , Isabell Speit , Anja von Heydebreck , Kevin M. Chin , Christopher Ryan Heery , James L. Gulley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immunotherapy and Biologic Therapy

Clinical Trial Registration Number

NCT01772004

Citation

J Clin Oncol 33, 2015 (suppl; abstr 3044)

DOI

10.1200/jco.2015.33.15_suppl.3044

Abstract #

3044

Poster Bd #

370

Abstract Disclosures

Similar Posters

First Author: Christopher Ryan Heery

First Author: Thorsten Oliver Goetze

First Author: Christopher Ryan Heery

First Author: Igor Tsaur